Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer

References

• American Cancer SocietyCancer facts and figures 2008 [Cited on Mar 13, 2009]. Available from: http://www.cancer.org.
   Google Scholar
• JemalASiegelRWardECancer statistics, 2008CA Cancer J Clin2008582719618287387
   PubMed Web of Science ®Google Scholar
• American Cancer SocietyBreast cancer facts and figures 2007–2008 [Cited on Mar 13, 2009]. Available from: http://www.cancer.org. Accessed March 13, 2009.
   Google Scholar
• BeslijaSBonneterreJBursteinHSecond consensus on medical treatment of metastatic breast cancerAnn Oncol200718221522516831851
   PubMed Web of Science ®Google Scholar
• FojoATMenefeeMMicrotubule targeting agents: basic mechanisms of multidrug resistance (MDR)Semin Oncol2005326 Suppl 7S3S816360716
   PubMed Web of Science ®Google Scholar
• GeneyRUngureanuMLiDOjimaIOvercoming multidrug resistance in taxane chemotherapyClin Chem Lab Med200240991892512435109
   PubMed Web of Science ®Google Scholar
• RowinskyEKThe development and clinical utility of the taxane class of antimicrotubule chemotherapy agentsAnnu Rev Med1997483533749046968
   PubMed Web of Science ®Google Scholar
• ValeroVHortobagyiGNAre anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?J Clin Oncol200321695996212637456
   PubMed Web of Science ®Google Scholar
• Gonzalez-AnguloAMMorales-VasquezFHortobagyiGNOverview of resistance to systemic therapy in patients with breast cancerAdv Exp Med Biol200760812217993229
   PubMed Web of Science ®Google Scholar
• KamathKWilsonLCabralFJordanMABetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instabilityJ Biol Chem200528013129021290715695826
   PubMed Web of Science ®Google Scholar
• PolliJWHumphreysJEHarmonKAThe role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactionsDrug Metab Dispos200836469570118216274
   PubMed Web of Science ®Google Scholar
• LeeJJSwainSMDevelopment of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR)Semin Oncol2005326 Suppl 7S22S2616360719
   PubMed Web of Science ®Google Scholar
• BollagDMMcQueneyPAZhuJEpothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of actionCancer Res19955511232523337757983
   PubMed Web of Science ®Google Scholar
• CortesJBaselgaJTargeting the microtubules in breast cancer beyond taxanes: the epothilonesOncologist200712327128017405891
   PubMed Web of Science ®Google Scholar
• NettlesJHLiHCornettBKrahnJMSnyderJPDowningKHThe binding mode of epothilone A on alpha, beta-tubulin by electron crystallographyScience2004305568586686915297674
   PubMed Web of Science ®Google Scholar
• FornierMNIxabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analoguesClin Breast Cancer200771075776318021476
   PubMed Web of Science ®Google Scholar
• Ixempra [package insert]Princeton (NJ)Bristol-Myers Squibb Company2009
   Google Scholar
• LeeFYWenMLShenHIxabepilone overcomes multiple mechanisms of drug resistance including overexpression of class III β-tubulin and breast cancer resistance proteinPresented at the 2008 European Breast Cancer Conference2008 Apr 15–19Berlin, Germany
   Google Scholar
• PerezEALerzoGPivotXEfficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabineJ Clin Oncol200725233407341417606974
   PubMed Web of Science ®Google Scholar
• ThomasESGomezHLLiRKIxabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatmentJ Clin Oncol200725335210521717968020
   PubMed Web of Science ®Google Scholar
• HortobagyiGNPerezEVrdoljakEAnalysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized phase III trialsPresented at the 2008 ASCO Breast Cancer Symposium2008 Sept 5–7Washington, DC Abstract 186.
   Google Scholar
• RochéHYelleLCognettiFPhase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapyJ Clin Oncol200725233415342017606972
   PubMed Web of Science ®Google Scholar
• ThomasETaberneroJFornierMPhase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancerJ Clin Oncol200725233399340617606975
   PubMed Web of Science ®Google Scholar
• MontoyaLManaging hematologic toxicities in the oncology patientJ Infus Nurs200730316817217505218
   PubMedGoogle Scholar
• MarrsJCare of patients with neutropeniaClin J Oncol Nurs200610216416616708700
   PubMedGoogle Scholar
• Camp-SorrellDMyelosuppressionItanoJKTaokaKNCore curriculum for oncology nursing4th edPhiladelphiaElsevier2005259274
   Google Scholar
• LymanGHLymanCHAgboolaORisk models for predicting chemotherapy-induced neutropeniaOncologist200510642743715967836
   PubMed Web of Science ®Google Scholar
• PolovichMWhiteJMKelleherLOChemotherapy and biotherapy guidelines and recommendations for practice2nd edPittsburghOncology Nursing Society2005
   Google Scholar
• MartinVRArthralgias and myalgiasYarbroCHFroggeMHGoodmanMCancer symptom management3rd edSudbury (MA)Jones and Bartlett20042025
   Google Scholar
• LeeJJSwainSMPeripheral neuropathy induced by microtubule-stabilizing agentsJ Clin Oncol200624101633164216575015
   PubMed Web of Science ®Google Scholar
• VisovskyCMeyerRRRollerJPoppasMEvaluation and management of peripheral neuropathy in diabetic patients with cancerClin J Oncol Nurs200812224324718390460
   PubMed Web of Science ®Google Scholar
• WickhamRChemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practiceClin J Oncol Nurs200711336137617623621
   PubMedGoogle Scholar
• OceanAJVahdatLTChemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapiesSupport Care Cancer200412961962515258838
   PubMed Web of Science ®Google Scholar
• PerezEPivotXVrdoljakEA prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancerPresented at the San Antonio Breast Cancer Symposium (SABCS)2008 Dec 10–14San Antonio (TX) Poster 6140.
   Google Scholar
• ArmstrongTAlmadronesLGilbertMRChemotherapy-induced peripheral neuropathyOncol Nurs Forum200532230531115759068
   PubMed Web of Science ®Google Scholar
• StillmanMCataJPManagement of chemotherapy-induced peripheral neuropathyCurr Pain Headache Rep200610427928716834943
   PubMedGoogle Scholar
• VisovskyCCollinsMAbbottLAschenbrennerJHartCPutting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathyClin J Oncol Nurs200711690191318063548
   PubMedGoogle Scholar
• StubblefieldMDVahdatLTBalmacedaCMTroxelABHesdorfferCSGoochCLGlutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic studyClin Oncol (R Coll Radiol)200517427127615997923
   PubMed Web of Science ®Google Scholar
• VahdatLPapadopoulosKLangeDReduction of paclitaxel-induced peripheral neuropathy with glutamineClin Cancer Res2001751192119711350883
   PubMed Web of Science ®Google Scholar
• MarkmanMPrevention of paclitaxel-associated arthralgias and myalgiasJ Support Oncol20031423323415334864
   PubMedGoogle Scholar
• WilkesGMBarton-BurkeMOncology nursing drug handbookSudbury (MA)Jones and Bartlett2006205208
   Google Scholar
• YennurajalingamSBrueraEFatigue and dyspneaPazdurRGoiaLRHoskinsWJCancer management: a multi-disciplinary approach10th edLawrence (KS)CMPMedica2007917927
   Google Scholar
• BarsevickAMNewhallTBrownSManagement of cancer-related fatigueClin J Oncol Nurs200812Suppl 5212518842521
   PubMed Web of Science ®Google Scholar
• MintonORichardsonASharpeMA systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigueJ Natl Cancer Inst2008100161155116618695134
   PubMedGoogle Scholar
• GelderblomHVerweijJNooterKSparreboomACremophor EL: the drawbacks and advantages of vehicle selection for drug formulationEur J Cancer200137131590159811527683
   PubMed Web of Science ®Google Scholar
• Taxol [package insert]Princeton (NJ)Bristol-Myers Squibb Company2007
   Google Scholar
• Drugs@FDA Web site. IXEMPRA Control Supplement Letter NDA22-065/S-001 [updated 2009 March 13; cited 2009 March 30]. Available from http://www.fda.gov/cder/foi/appletter/2009/022065s001ltr.pdf.
   Google Scholar